Novavax financials
$10.82+0.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.12B | $682.2M | $983.7M | $1.98B | $1.15B | $475.6M | $18.7M | $34.3M | $31.2M | $15.4M |
| Gross profit | $1.05B | $479.4M | $639.9M | $1.08B | $1.15B | $475.6M | $18.7M | $34.3M | $31.2M | $15.4M |
| Gross margin | 93.5% | 70.3% | 65.1% | 54.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $452.8M | -$248.9M | -$566.5M | -$644.7M | -$1.69B | -$416.7M | -$129.6M | -$173.9M | -$171.7M | -$269.1M |
| Net income | $440.3M | -$187.5M | -$545.1M | -$657.9M | -$1.74B | -$418.3M | -$132.7M | -$184.7M | -$183.8M | -$280.0M |
| Net margin | 39.2% | −27.5% | −55.4% | −33.2% | −152.1% | −87.9% | −711.0% | −538.8% | −589.5% | −1823.5% |
| Diluted EPS | $2.58 | $-1.23 | $-5.41 | $-8.42 | $-23.44 | $-7.27 | $-5.51 | $-9.99 | $-12.56 | $-20.60 |
| EBITDA | $578.3M | -$200.4M | -$525.3M | -$615.7M | -$1.67B | -$411.8M | -$123.9M | -$165.8M | -$161.9M | -$260.6M |
| Operating cash flow | -$244.6M | -$87.3M | -$714.0M | -$415.9M | $322.9M | -$42.5M | -$136.6M | -$184.8M | -$144.5M | -$258.8M |
| Free cash flow | -$251.0M | -$101.9M | -$772.8M | -$508.9M | $265.5M | -$97.2M | -$138.5M | -$186.2M | -$148.7M | -$277.0M |
| Diluted shares | 173.1M | 152.2M | 100.8M | 78.2M | 74.4M | 57.6M | 24.1M | 18.5M | 14.6M | 13.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $240.6M | $530.2M | $568.5M | $1.34B | $1.52B | $553.4M |
| Short-term investments | $494.4M | $392.9M | $0.00 | $0.00 | — | $157.6M |
| Total debt | $248.8M | $230.4M | $229.1M | $549.8M | $454.0M | $468.0M |
| Total assets | $1.18B | $1.56B | $1.80B | $2.26B | $2.58B | $1.58B |
| Total liabilities | $1.30B | $2.18B | $2.51B | $2.89B | $2.93B | $955.3M |
| Shareholders' equity | -$127.8M | -$623.8M | -$716.9M | -$634.1M | -$351.7M | $627.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology